Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients

Androgen deprivation therapy (ADT) is first‐line palliative treatment in androgen receptor‐positive (AR+) salivary duct carcinoma (SDC), and response rates are 17.6–50.0%. We investigated potential primary ADT resistance mechanisms for their predictive value of clinical benefit from ADT in a cohort...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Int J Cancer
Prif Awduron: van Boxtel, Wim, Verhaegh, Gerald W., van Engen‐van Grunsven, Ilse A., van Strijp, Dianne, Kroeze, Leonie I., Ligtenberg, Marjolein J., van Zon, Hans B., Hendriksen, Yara, Keizer, Diederick, van de Stolpe, Anja, Schalken, Jack A., van Herpen, Carla M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2019
Pynciau:
Tumor Markers and Signatures
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187215/
https://ncbi.nlm.nih.gov/pubmed/31745978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32795
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg